AMANDA BONE: Open Payments
NPI 1205609518 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 35 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $667 · 2025 $702
Food & beverage: $702
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 9 | $154 |
| ABBVIE INC. | 7 | $143 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $67 |
| PFIZER INC. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Lilly USA, LLC | 2 | $50 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| GENZYME CORPORATION | 2 | $31 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| QOL Medical, LLC | 1 | $24 |
Products named: XIFAXAN, CREON, ENTYVIO, IQIRVO, VELSIPITY, DUPIXENT, VIBERZI, OCALIVA.
Industry payments across PA — which companies pay providers there.
